Literature DB >> 33212117

Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer.

Francesca Perrone1, Emanuela Fabiola Craparo2, Maja Cemazar3, Urska Kamensek4, Salvatore Emanuele Drago2, Barbara Dapas1, Bruna Scaggiante1, Fabrizio Zanconati5, Debora Bonazza5, Mario Grassi6, Nhung Truong7, Gabriele Pozzato5, Rossella Farra8, Gennara Cavallaro9, Gabriele Grassi10.   

Abstract

Given the lack of effective treatments for Hepatocellular carcinoma (HCC), the development of novel therapeutic approaches is very urgent. Here, siRNAs were delivered to HCC cells by a synthetic polymer containing α,β-poly-(N-2-hydroxyethyl)-D,L-aspartamide-(PHEA) derivatized with diethylene triamine (DETA) and bearing in the side chain galactose (GAL) linked via a polyethylene glycol (PEG) to obtain (PHEA-DETA-PEG-GAL, PDPG). The GAL residue allows the targeting to the asialo-glycoprotein receptor (ASGPR), overexpressed in HCC cells compared to normal hepatocytes. Uptake studies performed using a model siRNA or a siRNA targeted against the enhanced green fluorescence protein, demonstrated the PDPG specific delivery of siRNA to HuH7 cells, a human cellular model of HCC. GAL-free copolymer (PHEA-DETA-PEG-NH2, PDP) or the chemical block of ASGPR, impaired PDPG targeting effectiveness in vitro. The specificity of PDPG delivery was confirmed in vivo in a mouse dorsal skinfold window chamber assay. Functional studies using siRNAs targeting the mRNAs of HCC-related genes (eEF1A1, eEF1A2 and E2F1) delivered by PDPG, significantly decreased HuH7 vitality/number and down regulated the expression of the target genes. Only minor effectiveness was in contrast observed for PDP. In IHH, a human model of normal hepatocytes with reduced ASGPR expression, PDPG barely reduced cell vitality. In a subcutaneous xenograft mouse model of HCC, PDPG-siRNAs reduced HCC tumor growth compared to controls without significant toxic effects. In conclusion, our study demonstrates the valuable potentials of PDPG for the specific delivery of siRNAs targeting HCC-related genes.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ASGPR targeted delivery; E2F1; Eukaryotic elongation Factor 1A; Hepatocellular carcinoma; siRNA

Year:  2020        PMID: 33212117     DOI: 10.1016/j.jconrel.2020.11.020

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  4 in total

1.  Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles.

Authors:  Chenghua Song; Jia Zhang; Ruichao Wen; Qingshan Li; Jiaxuan Zhou; Zheng Wu; Yi Lv; Rongqian Wu
Journal:  Mater Today Bio       Date:  2022-07-06

Review 2.  A review of the tortuous path of nonviral gene delivery and recent progress.

Authors:  Divya Sharma; Sanjay Arora; Jagdish Singh; Buddhadev Layek
Journal:  Int J Biol Macromol       Date:  2021-06-01       Impact factor: 8.025

3.  5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway.

Authors:  Federica Tonon; Maja Cemazar; Urska Kamensek; Cristina Zennaro; Gabriele Pozzato; Sergio Caserta; Flora Ascione; Mario Grassi; Stefano Guido; Cinzia Ferrari; Laura Cansolino; Francesco Trotta; Biljana Grcar Kuzmanov; Giancarlo Forte; Fabiana Martino; Francesca Perrone; Riccardo Bomben; Valter Gattei; Nicola Elvassore; Erminio Murano; Nhung Hai Truong; Michael Olson; Rossella Farra; Gabriele Grassi; Barbara Dapas
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

4.  Inhalable Formulation Based on Lipid-Polymer Hybrid Nanoparticles for the Macrophage Targeted Delivery of Roflumilast.

Authors:  Emanuela F Craparo; Marta Cabibbo; Cinzia Scialabba; Gaetano Giammona; Gennara Cavallaro
Journal:  Biomacromolecules       Date:  2022-07-28       Impact factor: 6.978

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.